Effect of acute GVHD on overall survival, disease-associated mortality, and treatment-related mortality after allogeneic hematopoietic cell transplantation for adult T-cell leukemia
| Outcome . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Overall survival* | ||||
| Grade 1 or 2 acute GVHD vs no acute GVHD | 0.60 (0.42-0.85) | .004 | 0.65 (0.45-0.93) | .018 |
| Grade 3 or 4 acute GVHD vs no acute GVHD | 1.38 (0.94-2.01) | .099 | 1.64 (1.10-2.42) | .014 |
| Disease-associated mortality† | ||||
| Grade 1 or 2 acute GVHD vs no acute GVHD | 0.47 (0.28-0.79) | .005 | 0.54 (0.32-0.92) | .023 |
| Grade 3 or 4 acute GVHD vs no acute GVHD | 0.41 (0.21-0.81) | .010 | 0.44 (0.22-0.90) | .024 |
| Treatment-related mortality‡ | ||||
| Grade 1 or 2 acute GVHD vs no acute GVHD | 1.13 (0.67-1.89) | .649 | 1.22 (0.72-2.07) | .461 |
| Grade 3 or 4 acute GVHD vs no acute GVHD | 3.34 (1.94-5.74) | < .001 | 3.50 (2.01-6.11) | < .001 |
| Outcome . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Overall survival* | ||||
| Grade 1 or 2 acute GVHD vs no acute GVHD | 0.60 (0.42-0.85) | .004 | 0.65 (0.45-0.93) | .018 |
| Grade 3 or 4 acute GVHD vs no acute GVHD | 1.38 (0.94-2.01) | .099 | 1.64 (1.10-2.42) | .014 |
| Disease-associated mortality† | ||||
| Grade 1 or 2 acute GVHD vs no acute GVHD | 0.47 (0.28-0.79) | .005 | 0.54 (0.32-0.92) | .023 |
| Grade 3 or 4 acute GVHD vs no acute GVHD | 0.41 (0.21-0.81) | .010 | 0.44 (0.22-0.90) | .024 |
| Treatment-related mortality‡ | ||||
| Grade 1 or 2 acute GVHD vs no acute GVHD | 1.13 (0.67-1.89) | .649 | 1.22 (0.72-2.07) | .461 |
| Grade 3 or 4 acute GVHD vs no acute GVHD | 3.34 (1.94-5.74) | < .001 | 3.50 (2.01-6.11) | < .001 |
Other significant variables were sex of recipient, female (reference, 1.00) and male (HR, 1.70; 95% CI, 1.24-2.32; P = .001); achievement of complete remission, complete remission (reference, 1.00), status other than complete remission (HR, 2.05; 95% CI, 1.44-2.92; P < .001), and status not known (HR, 2.21; 95% CI, 1.15-4.22; P = .017); type of donor, HLA-matched related donor (reference, 1.00), HLA-mismatched related donor (HR, 1.71; 95% CI, 1.04-2.84; P = .036), unrelated donor of bone marrow (HR, 1.39; 95% CI, 0.94-2.06; P = .096), and unrelated cord blood (HR, 1.86; 95% CI, 1.22-2.83; P = .004).
Other significant variables were achievement of complete remission, complete remission (reference, 1.00), status other than complete remission (HR, 2.98; 95% CI, 1.62-5.47; P < .001), and status not known (HR, 0.96; 95% CI, 0.21-4.49; P = .963); type of donor, HLA-matched related donor (reference, 1.00), HLA-mismatched related donor (HR, 2.14; 95% CI, 1.00-4.55; P = .049), unrelated donor of bone marrow (HR, 1.45; 95% CI, 0.81-2.61; P = .214), and unrelated cord blood (HR, 1.25; 95% CI, 0.63-2.49; P = .517).
Another significant variable was achievement of complete remission, complete remission (reference, 1.00), status other than complete remission (HR, 1.17; 95% CI, 0.74-1.84; P = .498) and status not known (HR, 2.31; 95% CI, 1.04-5.15; P = .040).